A new menin challenger
Hutchmed starts phase 1 with a project in a field where Syndax and Kura have so far been the main players.
AACR 2024 – Transgene gets a “vaccine” boost
Early data with the group’s personalised project intrigue, but Transgene has a long road ahead.
AACR 2024 – BioNTech sees pancreatic promise amid neoantigen delays
When autogene cevumeran works it seems to keep working, but bigger tests for the project have been pushed back.
AACR 2024 preview – “cancer vaccines” primed to underwhelm
Projects from the likes of BioNTech, Transgene and Scancell will feature, but still have much to prove.
OncoC4 takes its Siglec-10 bet into the clinic
The anti-Siglec-10 MAb ONC-841 features among the latest crop of first-in-human trial initiations.
